.
MergerLinks Header Logo

Announced

Completed

RA Capital, Venrock and CMG-SDIC led a $310m funding round in LianBio.

Financials

Edit Data
Transaction Value£239m
Consideration TypeCash
Capital Owned-
Capital Bid For-
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Pharmaceuticals

China

Private

Single Bidder

medicine company

Minority

Cross Border

biomedicine

Acquisition

Venture Capital

Friendly

Private Equity

Completed

Synopsis

Edit

Private equity firms RA Capital, Venrock and CMG-SDIC led a $310m funding round in LianBio, a medicine manufacturer. Other specialist investors in the round included funds and accounts managed by BlackRock, Casdin Capital, Farallon, Logos Capital, Perceptive Advisors, Pfizer, Sphera Healthcare, funds and accounts advised by T. Rowe Price, Tybourne Capital Management, Vida Ventures, Viking Global Investors and Wellington Management. "We are excited to partner with this world-class group of investors who share our vision of accelerating broad access to transformative medicines for patients in China and other major Asian markets. Building on the success and momentum of the Company’s recent launch, this financing provides additional support for LianBio’s efforts to contribute to China’s dynamic life sciences landscape by addressing significant unmet medical needs in the region,” Konstantin Poukalov, Perceptive Advisors Managing Director.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US